Pediatrix Medical Group, Inc.
In the published model solve dated 2026-Q2, anchored at $26.02, Pediatrix Medical Group, Inc. (MD) is priced for +0.1% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 24, 2026 from SEC EDGAR filings.
• This is a physician services company whose doctors staff hospital neonatal and maternal-fetal units under contract, so 85% of what it collects is billed per patient and the rest is an administrative fee the hospital pays for running the unit. • Volumes are the structural problem: same-unit patient volume fell 1.6% in the first quarter while reimbursement and payer mix added 4.4% [Source: Pediatrix Q1 2026 results, May 5, 2026], which means every dollar of growth currently comes from rate rath
Is MD overvalued? See what's priced in →
285 institutional managers reported holding MD in 13F filings for the quarter ended 2026-03-31. 31 opened new positions that quarter. Held by BlackRock, Vanguard Group, Dimensional Fund Advisors, among others. On the short side, 3.8M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (5.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
MD has cut its share count 4.7% over the past five years, spending $201.74M on repurchases. It pays no dividend. Cash returned over the past three years: $109.97M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at MD over the trailing three years. Absence is a fact about the company, not a signal. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
MD's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | +5.9% | -12.1% |
| 2023-11-03 | -11.8% | -2.1% |
| 2024-02-21 | -6.6% | +6.5% |
| 2024-05-08 | -8.4% | -20.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
MD's latest 8-K filings: 2026-08-04 (items 2.02, 9.01); 2026-07-24 (items 5.02, 7.01); 2026-07-15 (items 2.02, 7.01, 9.01); 2026-05-07 (items 5.02, 5.07, 9.01); 2026-05-05 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 24, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.